Roche Primes New Push Via Cipla For Avastin, Actemra In India

Roche Products (India) Private Limited has teamed up with Cipla Ltd. to push its Avastin (bevacizumab) second brand and the arthritis treatment tocilizumab (Actemra) on the Indian market, as it seeks to take on competition and expand access to its therapies.

 The deal, which marks the coming together of less natural allies traditionally on opposite sides of the debate on most aspects of pharma, is expected to up the competition quotient in the bevacizumab space which has seen the entry of multiple biosimilar versions